Update on AI in pharmacovigilance at EMA

Industry Stakeholder Platform – Operation of EU Pharmacovigilance
22 November 2023

Presented by Julie Durand | Pharmacovigilance Office
Acknowledgements: Luis Pinheiro | Data Analytics and Methods Taskforce
Artificial Intelligence at EMA | Drivers

**Process Analytics**
Improving knowledge management and efficiency by streamlining and automating digital processes

**Regulatory submissions**
Regulate applications of AI in medicines with a view to help create value for public health

**Healthcare data analytics**
Structure information and increase insights into data to inform decision-making

**External collaboration**
Be an effective collaborator, including on legislation and guidance development
AI at EMA | Operational aspects

**AI Coordination Group:** promote oversight and a harmonised approach with EMA initiatives as well as legislative and international initiatives in the field of AI

**AI Technical Group:** community of practice that supports AI Coordination Group

Close interaction and cooperation are ensured with the **Big Data Steering Group** and the Agency’s committees and WPs, in particular the Methodology Working Party (MWP).

Two **task forces** established to **develop capabilities** in the use of AI in data analytics and process analytics and to **strengthen collaboration** across the Agency.

**DigiLab:** provides a prioritisation and experimentation framework, supporting the following:

- **Analytics Centre of Excellence** (ACE): explore how AI can support business needs and deliver solutions
- **Health Data Lab:** leverage novel digital technologies using healthcare data (e.g. pharmacovigilance)
Reflection paper

Reflection paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle
Draft

Overall vision: allow companies to extract potential benefits from the use of AI for public health while ensuring that risks are managed and mitigated.

"It is foreseen that AI/ML tools can effectively support [...] pharmacovigilance activities including adverse event report management and signal detection, in line with current good pharmacovigilance practices requirements."

"Applications within pharmacovigilance may allow a more flexible approach to AI/ML modelling, where incremental learning can continuously enhance models for classification and severity scoring of adverse event reports as well as signal detection."

"It remains the responsibility of the MAH to validate, monitor and document model performance and include AI/ML operations in the pharmacovigilance system, to mitigate risks related to all algorithms and models used."

Public workshop 20-21 Nov 2023
"Smart regulation in a rapidly evolving world"
✓ engage stakeholders
✓ inform on HMA/EMA activities
✓ discuss the draft AI reflection paper
Pharmacovigilance: a good fit for AI

- Procedures are elaborate, mature, and high-sensitivity: good fit for automation and allow for some error tolerance.
- Multiple information flows are required including scientific literature, regulatory documentation.
- ICSRs carry a wealth of unstructured information.
- At times faced with high velocity data, can benefit from methods that help scale processes.
- Error tolerance affects trade-off between explainability and performance on a risk-based approach.
## AI in pharmacovigilance | Opportunities in signal detection

### ICSR data
- Deduplication
- Structuring
  - text data

### Summary report
- AI-enhanced
  - SDRs

### Potential signals
- AI-enhanced
  - prioritisation

### Case line listing
- AI-enhanced signal review
  - Automated adjudication of
    - cases (filtering)

### Tracking
- AI-enhanced
  - prioritisation

<table>
<thead>
<tr>
<th>DRUG</th>
<th>ADR</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>A</td>
<td>10</td>
</tr>
<tr>
<td>X</td>
<td>B</td>
<td>12</td>
</tr>
<tr>
<td>Y</td>
<td>A</td>
<td>4</td>
</tr>
<tr>
<td>Y</td>
<td>F</td>
<td>34</td>
</tr>
<tr>
<td>Z</td>
<td>B</td>
<td>12</td>
</tr>
<tr>
<td>Z</td>
<td>K</td>
<td>4</td>
</tr>
<tr>
<td>...</td>
<td>...</td>
<td>8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DRUG</th>
<th>ADR</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>A</td>
<td>check</td>
</tr>
<tr>
<td>Z</td>
<td>K</td>
<td>check</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#1</th>
<th>NL</th>
<th>Drugs</th>
<th>Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>#2</td>
<td>FR</td>
<td>Drugs</td>
<td>Reactions</td>
</tr>
<tr>
<td>#3</td>
<td>PT</td>
<td>Drugs</td>
<td>Reactions</td>
</tr>
<tr>
<td>#4</td>
<td>SK</td>
<td>Drugs</td>
<td>Reactions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#1</th>
<th>DE</th>
<th>Drugs</th>
<th>Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>#2</td>
<td>SP</td>
<td>Drugs</td>
<td>Reactions</td>
</tr>
<tr>
<td>#3</td>
<td>PT</td>
<td>Drugs</td>
<td>Reactions</td>
</tr>
<tr>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
</tbody>
</table>
AI in PV | EMA experiments

- **Extraction of ADRs** from SmPCs
- **Probabilistic phenotyping**: identify patients likely to have a certain genotype by modelling ADR manifestation (*example: 5-FU toxicity*)
- **Literature screening**: identify articles containing ADRs, prioritise articles most likely to trigger signals
- **Automated case adjudication**: improve scalability of processes by identifying most supportive cases (*example: thrombosis with thrombocytopenia syndrome*)
- **Prioritisation of potential signals** based on historical data
- **Screening of PSURs** for signal discussions
- **Prediction model for drug abuse**
- ...

6 AI in pharmacovigilance - EMA update
AI in PV | New collaborations

**CIOMS Working Group XIV on AI in Pharmacovigilance**
- Formed in 2022, drafting group of senior experts in PhV and/or AI from regulators, industry, research organisations, academia, WHO
- Objective of future report: provide framework for critical appraisal, implementation, maintenance of AI solutions for pharmacovigilance

**FDA/EMA cluster on AI in Pharmacovigilance**
- Objectives:
  - Exchange and explore alignment on policies, guidance and regulation
  - Foster leadership and collaboration on international regulatory initiatives
  - Share experience and lessons learnt on use cases
  - Discuss research needs
- 2-monthly TCs, kick-off in Oct. 2023
Final thoughts

EMA general approach on AI...

1. **support** medicines developers with agile guidance development and early **dialogue**
2. **experiment** in process and healthcare data analytics
3. **monitor** developments in AI technology and policy

...including PV

- Open to dialogue on experience, plans & concerns
- Potential focus area for MWP
- Learn about opportunities & challenges
Thank you for your attention

Further information

Julie Durand julie.durand@ema.europa.eu
European Medicines Agency
Send a question via our website www.ema.europa.eu/contact

Follow us on @EMA_News